Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is well-positioned in the growing precision medicine market, with a strong focus on next-generation sequencing and AI-powered solutions. They have a diverse portfolio of molecular diagnostic tests for cancer, and their partnerships with biopharma companies provide opportunities for growth. With a solid financial standing and continued innovation, Caris is poised for success in the future.

Bears say

Caris Life Sciences is a patient-centric, next-generation AI TechBio company that specializes in comprehensive molecular information and AI/ML algorithms. Despite strong financial performance in Q2, with a beat in revenue and EBITDA, as well as strong volume growth, analysts have a negative outlook on the stock due to several reasons. These include pricing concerns for their new Caris Detect early cancer detection test, uncertainty surrounding FDA clearance and reimbursement, competition in the precision oncology space, and potential litigation and legal risks. This negative outlook is also reflected in the company's current stock price, trading at a significant discount to its peers and a recent dip in valuations for growth stocks and diagnostics. Additionally, there is some risk associated with the company's balance sheet as they may require additional capital to further invest in their business. Despite these challenges, Caris Life Sciences remains well-positioned and has a strong track record of growth, with a leading investor base and a recent successful IPO. However, this analyst believes that the company's current stock price does not fully reflect these strengths, leading to a negative outlook on the stock.

CAI (CAI) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 9 analysts, CAI (CAI) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.